A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (CheckMate-1533)
A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent NSCLC
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: First line of the email MUST contain NCT # and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
-
São Paulo, Brazil, 01246-000
- Local Institution - 0034
-
-
Federal District
-
Brasília, Federal District, Brazil, 70200-730
- Local Institution - 0041
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30380-490
- Local Institution - 0043
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903
- Local Institution - 0038
-
-
São Paulo
-
Barretos, São Paulo, Brazil, 14784400
- Local Institution - 0037
-
-
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 8420383
- Local Institution - 0067
-
-
-
-
Côte-d'Or
-
Dijon, Côte-d'Or, France, 21079
- Local Institution - 0065
-
-
Hauts-de-Seine
-
Suresnes, Hauts-de-Seine, France, 92151
- Local Institution - 0003
-
-
Île-de-France Region
-
Paris, Île-de-France Region, France, 75014
- Local Institution - 0010
-
-
-
-
Attikí
-
Athens, Attikí, Greece, 115 27
- Local Institution - 0012
-
Chaïdári, Attikí, Greece, 12462
- Local Institution - 0013
-
-
Kentrikí Makedonía
-
Thessaloniki, Kentrikí Makedonía, Greece, 540 07
- Local Institution - 0011
-
-
Thessalía
-
Larissa, Thessalía, Greece, 41110
- Local Institution - 0014
-
-
-
-
-
Novara, Italy, 28100
- Local Institution - 0017
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italy, 47014
- Local Institution - 0015
-
-
Friuli Venezia Giulia
-
Udine, Friuli Venezia Giulia, Italy, 33100
- Local Institution - 0057
-
-
Lombardy
-
Bergamo, Lombardy, Italy, 24127
- Local Institution - 0020
-
-
Tuscany
-
Florence, Tuscany, Italy, 50134
- Local Institution - 0019
-
-
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Poland, 03-411
- Local Institution - 0081
-
-
Pomeranian Voivodeship
-
Prabuty, Pomeranian Voivodeship, Poland, 82-550
- Local Institution - 0080
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Poland, 93-338
- Local Institution - 0079
-
-
-
-
-
Bucharest, Romania, 020335
- Local Institution - 0075
-
Cluj-Napoca, Romania, 400015
- Local Institution - 0074
-
Iași, Romania, 700483
- Local Institution - 0078
-
-
Bucharest
-
Bucharest, Bucharest, Romania, 022328
- Local Institution - 0073
-
-
Cluj
-
Florești, Cluj, Romania, 407280
- Local Institution - 0076
-
-
Dolj
-
Craiova, Dolj, Romania, 200542
- Local Institution - 0077
-
-
-
-
GP
-
Sandton, GP, South Africa, 2196
- Local Institution - 0009
-
-
Gauteng
-
Soweto, Gauteng, South Africa, 2013
- Local Institution - 0031
-
-
Western Cape
-
Rondebosch, Western Cape, South Africa, 7700
- Local Institution - 0084
-
-
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
- Local Institution - 0032
-
-
California
-
Los Angeles, California, United States, 90033
- Local Institution - 0062
-
-
Idaho
-
Boise, Idaho, United States, 83702
- Local Institution - 0063
-
Boise, Idaho, United States, 83706
- Local Institution - 0052
-
Post Falls, Idaho, United States, 83854
- Local Institution - 0064
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Local Institution - 0047
-
Cleveland, Ohio, United States, 44109
- Local Institution - 0033
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Local Institution - 0051
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Participants must have histologically confirmed stage IV or recurrent non-small cell lung cancer (NSCLC) (as defined by the 9th edition of the IASLC Lung Cancer Staging Guidelines) of squamous or non-squamous histology.
- Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therapy for advanced or metastatic disease.
- Participants with prior definitive chemoradiation for locally advanced disease is permitted as long as the last administration of chemotherapy or radiotherapy (whichever was given last) occurred at least 6 months prior to randomization. Participants with locally advanced disease with recurrence after chemoradiation therapy (stage III disease, specifically refers to patients with no curative options) are eligible to enroll.
- Participants with prior adjuvant or neoadjuvant chemotherapy for early-stage lung cancer are permitted if completed at least 6 months prior to randomization.
- Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1 at screening and confirmed prior to randomization.
- Participants must have measurable disease by CT or MRI per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with radiographic tumor assessment performed within 28 days of randomization.
Exclusion Criteria
- Participants must not have any prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- Participants must not have any known driver mutations with available targeted therapy (including but not limited to EGFR mutations, ALK translocations, ROS-1 translocations and known BRAFV600E, that are sensitive to available targeted inhibitor therapy; participants with a known activating RET mutations and NTRK fusion gene alterations).
- Participants must not have any untreated central nervous system (CNS) metastases
- Participants must not have leptomeningeal metastases (carcinomatous meningitis).
- Participants must not have any active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Participants with previous malignancies (except non-melanoma skin cancers, and in situ cancers such as the following: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to randomization and no additional therapy is required or anticipated to be required during the study period.
- Participants must not have a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- Participants must not have any history of interstitial lung disease or pneumonitis that required oral or IV glucocorticoids to assist with management.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm A
|
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
|
Experimental: Arm B
|
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum observed serum concentration (Cmax) of subcutaneous Nivolumab in serum
Time Frame: Up to 3 weeks
|
Up to 3 weeks
|
|
Time to peak concentration (Tmax) of subcutaneous Nivolumab in serum
Time Frame: Up to 3 weeks
|
Up to 3 weeks
|
|
Area under the concentration-time curve within a dosing interval (AUC(TAU)) of subcutaneous Nivolumab in serum
Time Frame: Up to 3 weeks
|
Up to 3 weeks
|
|
Concentration at the end of a dosing interval (Ctau) of subcutaneous Nivolumab in serum
Time Frame: Up to 3 weeks
|
Up to 3 weeks
|
|
Trough observed concentration (Ctrough) of subcutaneous Nivolumab
Time Frame: At Cycle 7 Day 1 (Week 18)
|
At Cycle 7 Day 1 (Week 18)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with AEs leading to discontinuation
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of deaths
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of participants with adverse events (AEs)
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of participants with serious adverse events (SAEs)
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of participants with drug related AEs
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of participants with Immune Mediated Adverse Events (IMAEs)
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of participants with anti-nivolumab antibodies
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of participants with anti-ipilimumab antibodies
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of participants with neutralizing antibodies
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Cmax of intravenous Ipilimumab in serum
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
|
Tmax of intravenous Ipilimumab in serum
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
|
AUC(TAU) of intravenous Ipilimumab in serum
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
|
Ctau of intravenous Ipilimumab in serum
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Inorganic Chemicals
- Chlorine Compounds
- Nitrogen Compounds
- Coordination Complexes
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Amino Acids, Acidic
- Amino Acids
- Amino Acids, Dicarboxylic
- Taxoids
- Cyclodecanes
- Diterpenes
- Platinum Compounds
- Nivolumab
- Pemetrexed
- Ipilimumab
- Carboplatin
- Paclitaxel
- Cisplatin
Other Study ID Numbers
Other Study ID Numbers
- CA209-1533
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.